OOIR: Observatory of International Research

Papers

(The TQCC of Nature Reviews Cancer is 31. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-07-01 to 2025-07-01.)

Article	Citations
Linking pancreatic renewal and cancer initiation	1473
Computing brain metastasis impact	1233
Digging for treasures in the tumour interactome	1045
INVADEseq to study the intratumoural microbiota at host single-cell resolution	886
An inhospitable site	541
Convergent inducers and effectors of T cell paralysis in the tumour microenvironment	507
Fructose takes a detour to feed cancer	471
Combinatorial strategies to target RAS-driven cancers	397
Artificial intelligence in cancer research, diagnosis and therapy	347
Emerging strategies to investigate the biology of early cancer	337
Oncofetal reprogramming in tumour development and progression	336
Mapping the prostate cell family tree	318
How medical anthropology can contribute to cancer research	290
Author Correction: Fighting rare cancers: lessons from fibrolamellar hepatocellular carcinoma	288
Connie J. Eaves (1944–2024)	281
The recruitment of metastasis-associated monocytes	278
Antihistamines boost immunotherapy	266
Fighting cancer with fat	262
The role of CRAF in cancer progression: from molecular mechanisms to precision therapies	256
Tertiary lymphoid structures as hubs of antitumour immunity	250
Reply to ‘Heterogeneity of TP53 mutations necessitates differentiation with p53-rescue therapies’	242
Targeting transcription cycles in cancer	238
Beyond genetics: driving cancer with the tumour microenvironment behind the wheel	229
Translating premalignant biology to accelerate non-small-cell lung cancer interception	225
Context-dependent functions of pattern recognition receptors in cancer	220

Epithelial and stromal co-evolution and complicity in pancreatic cancer	211
No mutation, tumour initiation	207
Impersonating neurons	206
Under pressure	204
Nanoreceptors take down mutant p53	202
Defining a ‘cells to society’ research framework for appendiceal tumours	192
Gut microbes produce novel genotoxic metabolites	179
Tumour EVPs disrupt liver function	176
Dendritic cells rise and shine	169
Removing barriers to address sex differences in anticancer drug toxicity	169
Persistence is key	167
Thelpers? More like Ttroublemakers	166
How chemokines organize the tumour microenvironment	165
Moonlighting functions of glucose metabolic enzymes and metabolites in cancer	165
AACR 2025	160
Measuring HLA disruption using MHC Hammer	158
Tumour–host interactions through the lens of Drosophila	156
Remodelling of the tumour microenvironment by the kallikrein-related peptidases	150
Natural killer cells in antitumour adoptive cell immunotherapy	147
3D bioprinted cancer models: from basic biology to drug development	147
Points of entry for tumour-infiltrating lymphocytes	146
B-ring sterols to the rescue	144
Bone voyage: immune crosstalk sets sail	139
In-depth organoid profiling of pancreatic cancer	138
Identifying spatial cellular structures with SPACE-GM	138
Visualizing intratumoural heterogeneity with EpicMIBI	137
Un-Fair Skin: racial disparities in acral melanoma research	133
The plasticity of mRNA translation during cancer progression and therapy resistance	131
Linking cell mechanical memory and cancer metastasis	120
The path to leptomeningeal metastasis	119
Metabolic interplays between the tumour and the host shape the tumour macroenvironment	118
Leveraging the replication stress response to optimize cancer therapy	115
Regulatory T cells in the tumour microenvironment	108
In situ decellularization of tissues to resolve the tumour-associated matrix	104
Dynamics and specificities of T cells in cancer immunotherapy	104
Deciphering the cancer genome and epigenome	100
Understanding and addressing race disparities in childhood cancer outcomes	100
Encoding spatial tumour dynamics with Starfysh	93
Taming TAMs in brain metastases	91
Race influences the tumour microbiome	89
Don’t blame the messenger: lessons learned for cancer mRNA vaccines during the COVID-19 pandemic	89
The link between vitamin D and prostate cancer	89
Polygenic scores in cancer	88
Targeted protein degradation for cancer therapy	87
Acetyl-CoA metabolism in cancer	87
Cancer nanomedicine	87
RNA splicing dysregulation and the hallmarks of cancer	86
Local CAR manufacturing	84
Z-nucleic acids give immunotherapy a boost	84
Author Correction: Antibody-based proteomics: fast-tracking molecular diagnostics in oncology	83

Right ON target: a new RAS-GTP inhibitor	82
Parity modulates epithelial–immune cell communication	82
A trojan horse to target spliceosome mutant cells	79
Prime editing GEMMs to model cancer mutations	79
Androgen receptor signalling in non-prostatic malignancies: challenges and opportunities	78
Expanding the utility of precision oncology knowledge bases	78
Integrative medicine in oncology: redefining the standard of care	77
Defining precancer: a grand challenge for the cancer community	76
NOTUM-mediated stem cell competition in CRC	75
Chromothripsis in cancer	75
Targeting ferroptosis as a vulnerability in cancer	71
Tertiary lymphoid structures in anticancer immunity	71
Starting a new job	68
Glycogen condensates drive tumorigenesis by trapping Hippo kinases	67
Quantum probes in cancer research	65
Functional lineage tracing to study the clonal evolution of therapy resistance	64
Neutrophils: a roadblock for immunotherapy	61
Revealing genomic secrets of archival FFPE samples	59
In vivo labelling system to study cell neighbourhoods	59
Judith Campisi (1948–2024)	58
New pathogen on the block	58
Inferring cancer metabolism from gene-expression data	56
Recent advances in therapeutic cancer vaccines	56
The present and future of the Cancer Dependency Map	55
Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart	53
Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data	52
Cell states can give tumorigenesis a head start	46
Carcinogenesis at single-cell resolution	46
Microbiota links to immunotherapy toxicity	45
Bidirectional CART.BiTE cells bring new hope	44
Patient-derived organoids unveil sarcoma vulnerabilities	43
Epigenomic heterogeneity as a source of tumour evolution	43
Global post-mortem tissue donation programmes to accelerate cancer research	41
Transfer RNAs as dynamic and critical regulators of cancer progression	39
Evolution and progression of Barrett’s oesophagus to oesophageal cancer	38
A timeline of tumour-associated macrophage biology	38
Developing dietary interventions as therapy for cancer	38
Traject3d for studying 3D cellular heterogeneity	35
Author Correction: Integrative medicine in oncology: redefining the standard of care	33
We cannot ignore the cancer risks of wildfires	32
Neuro-immune cross-talk in cancer	32
Guardrails for the use of generalist AI in cancer care	31